Deadline: 12-Nov-2025
The Pfizer and Astellas have announced a new grant opportunity designed to advance independent medical education for healthcare professionals involved in the care of patients with muscle-invasive bladder cancer (MIBC).
This initiative seeks to address current gaps in the rapidly evolving treatment landscape and highlight how emerging clinical data can influence and transform medical practice in the management of bladder cancer.
The program specifically aims to support educational projects that enhance awareness and understanding of MIBC among healthcare professionals across the United States. Proposed initiatives should focus on improving knowledge of treatment outcomes with currently available systemic therapies, with particular emphasis on patients who have limited or no existing treatment options. Applicants are also encouraged to explore educational strategies that help deepen clinicians’ understanding of new therapeutic advancements and how these may reshape clinical decision-making.
Eligible projects may request up to $220,000 in funding, with a project duration of 18 to 24 months. The grants will support programs that are scientifically sound, unbiased, and independently developed, ensuring that participating healthcare professionals gain valuable, evidence-based insights into evolving standards of care.
The target audience for this opportunity includes surgical urologists, urologists, uro-oncologists, medical oncologists, advanced practitioners, nurses, and other multidisciplinary team members involved in treating patients with urothelial cancer. The goal is to equip these professionals with the latest clinical knowledge, foster collaboration across disciplines, and improve patient outcomes through more informed treatment decisions.
Eligible applicants include medical, nursing, pharmacy, and allied health schools, healthcare institutions, professional organizations, medical societies, and medical education companies dedicated to advancing healthcare professional training and patient care. Only organizations—not individuals or independent medical practice groups—are eligible to apply. Collaborative proposals involving multiple departments or institutions are welcome, provided all participating entities have a relevant role in the project.
Applicants must ensure they are legally able to receive funds directly from Pfizer Inc., and those offering continuing education must hold appropriate accreditation. This collaborative initiative between Pfizer and Astellas represents a significant opportunity to strengthen clinical education and support healthcare providers in navigating the complexities of modern MIBC treatment, ultimately improving the quality of care for patients across the United States.
For more information, visit Pfizer.